Homatropine ophthalmic Side Effects
Medically reviewed by Drugs.com. Last updated on Jul 22, 2022.
Applies to homatropine ophthalmic: ophthalmic solution.
Side effects include:
Elevated IOP, transient stinging, burning. With prolonged administration, local irritation (characterized by follicular conjunctivitis, vascular congestion, edema, exudate, and eczematoid dermatitis ), thirst, dry mouth, increased light sensitivity of eyes.
For Healthcare Professionals
Applies to homatropine ophthalmic: compounding powder, ophthalmic solution.
The most frequently reported side effects were transient stinging/burning upon instillation and increased sensitivity to light.[Ref]
Common (1% to 10%): Transient burning, transient stinging, increased sensitivity to light
Uncommon (0.1% to 1%): Eye irritation
Rare (0.01% to 0.1%): Local irritation, vascular congestion, edema, exudates, eczematoid dermatitis, follicular conjunctivitis
Rare (0.01% to 0.1%): Thirst, dryness of mouth
Frequency not reported: Abdominal distention infants, gastrointestinal motility diminished, salivary secretion decreased, sweat gland secretion decreased[Ref]
Frequency not reported: Ataxia, incoherent speech, hyperactivity, seizure, unusual drowsiness
Postmarketing reports: Somnolence[Ref]
Frequency not reported: Restlessness, hallucination, disorientation, failure to recognize people
Postmarketing reports: Confusion[Ref]
Frequency not reported: Hyperpyrexia[Ref]
Postmarketing reports: Heart rate increased[Ref]
More about homatropine ophthalmic
- Check interactions
- Reviews (1)
- Latest FDA alerts (1)
- Dosage information
- During pregnancy
- Drug class: mydriatics
- En español
Related treatment guides
1. Cerner Multum, Inc. "Australian Product Information." O 0
2. "Product Information. Homatropine Hydrobromide (homatropine ophthalmic)." OCuSOFT (2017):
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Some side effects may not be reported. You may report them to the FDA.